Default company panoramic image

Apollo Diagnostics LLC

Apollo will develop non-invasive signatures for early cancer detection and prediction of risk, progression and outcomes of proposed therapy.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Washington, D.C., DC, USA
  • Currency USD
  • Founded December 2011
  • Employees 2
  • Website

Company Summary

For cancer patients and pharmaceutical companies worldwide who annually spend over 10 billion dollars on biomarker discovery and diagnostics, Apollo’s multivariate non-invasive cancer signatures integrate all the metabolites, proteins and genetic factors that accurately predict clinical performance in diagnostics, as well as prognosis of disease progression, patient’s response to treatment options and the outcomes of the proposed therapy.


  • Default avatar
    Martin N. Martinov
    Chief Technology Officer

    Dr. Martinov has implemented extensive IT solutions in pharmaceuticals, diagnostics, and imaging. He holds an MS in Biotechnology from University of Sofia, Bulgaria, a PhD in Molecular Biophysics from Florida State University, Tallahassee, FL and has done post-doctoral research at Rensselaer Polytechnic Institute, Troy, NY.

  • Default avatar
    Nikola K. Kaludov
    Scientific Operations

    Dr. Kaludov is an experienced executive with extensive R&D expertise and a successful industry track record. As an industry executive has transformed two biotechnology research platforms into product pipelines, taken a product through pre-clinical development and IND, and founded one biotechnology company. Nick holds a PhD from Florida State University, a M.S. from University of Sofia and has done post-doctoral studies at the NIH, Bethesda, MD.


  • Default avatar
    Jim U. Jensen, JD, MBA
    Default avatar
    A. Murat Croci, CPA